¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
°¢¸· ÀÓÇöõÆ® ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¼¼°è °¢¸· ÀÓÇöõÆ® ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 6.5%·Î 2030³â±îÁö 6¾ï 9,500¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿øÃß°¢¸·, ÈÄÅ©½º °¢¸·ÀÌ»óÁõ, °¨¿°¼º °¢¸·¿°°ú °°Àº °¢¸· ÁúȯÀÇ À¯º´·ü Áõ°¡´Â »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¼ö¿ä¿Í °ø±ÞÀÇ °ÝÂ÷µµ Àå±âÀûÀ¸·Î »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¢¸· ±âÁõÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀ» È®»ê½ÃŰ´Â ´Ù¾çÇÑ ÇÁ·Î±×·¥µµ »ê¾÷ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, À¯·´ÀÇ ¸¹Àº ±¹°¡µéÀº °¢¸· À̽Ŀ¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Àå±â ±âÁõ¿¡ ´ëÇÑ '¿ÉÆ®¾Æ¿ô' Á¤Ã¥À» äÅÃÇϰí ÀÖ½À´Ï´Ù.
°¢¸· À̽İú °ü·ÃµÈ R&D Ȱµ¿ÀÌ Áõ°¡ÇÏ¸é¼ ¿¹Ãø ±â°£ µ¿¾È ¾÷°èÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹ÙÀÌ¿À ¿£Áö´Ï¾î¸µ °¢¸·, 3D ÇÁ¸°ÅÍ °¢¸·, Áٱ⼼Æ÷ Ä¡·á´Â ÀÌÇØ°ü°èÀÚµéÀÇ °ü½ÉÀ» ²ø°í ÀÖ´Â ÁÖÁ¦ Áß ÀϺÎÀÔ´Ï´Ù. ¶ÇÇÑ, À¯¸®ÇÑ »óȯ ½Ã³ª¸®¿À, ½ÅÁ¦Ç° °³¹ß¿¡ ´ëÇÑ Á¦Á¶¾÷üÀÇ ÁýÁßµµ Áõ°¡, ÇâÈÄ 2³â°£ ¿¹»óµÇ´Â ½ÅÁ¦Ç° Ãâ½Ã´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ¹ÙÀÌ·¯½º È®»êÀ» ¸·±â À§ÇÑ ¿¹¹æ Á¶Ä¡·Î ½ÃÇàµÈ ¼ö¼ú °Ç¼ö °¨¼Ò À¸·Î ÀÎÇØ °¢¸· ÀÓÇöõÆ® ÆÇ¸Å°¡ ÀϽÃÀûÀ¸·Î Áö¿¬µÇ°í ÀÖ½À´Ï´Ù.
±×·¯³ª ¼¼°è°¡ Á¤»óÀ¸·Î µ¹¾Æ¿Â Áö±Ý, ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È Äڷγª ÀÌÀüÀÇ ¼ºÀå·üÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÏ¹Ì´Â 2021³â¿¡ Àü ¼¼°è »ê¾÷À» ÁÖµµÇϸç Àüü ¸ÅÃâ¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¹Ì±¹Àº Àü ¼¼°è °¢¸· ÀÓÇöõÆ®ÀÇ ÁÖ¿ä °ø±Þ¾÷ü Áß ÇϳªÀ̱⠶§¹®¿¡ ÀÌ Áö¿ªÀº 2022³âºÎÅÍ 2030³â±îÁö ¾ÈÁ¤ÀûÀÎ CAGR·Î ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Áß±¹, Àεµ³×½Ã¾Æ, Çʸ®ÇÉ µîÀÇ ±¹°¡¿¡¼ °¢¸· ÀÓÇöõÆ® ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°¢¸· ÀÓÇöõÆ® ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
- À¯Çüº°·Î´Â Àΰ£ °¢¸· ºÎ¹®ÀÌ 2022³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ÃßÁ¤ ¹× ¿¹Ãø ±â°£ µ¿¾È ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- Á¢±Ù¼º ºÎÁ·, Àΰ£ °¢¸· ºÎÁ·, ÀÌ½ÄÆí °ÅºÎ¹ÝÀÀ »ç·ÊÀÇ Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ³»Çǰ¢¸·À̽ļú ºÎ¹®Àº °¨¿° ¹× ¾È±¸ Ç¥¸éÀÇ »ç°í À§Çè °¨¼Ò·Î ÀÎÇÑ ´õ ºü¸£°í ÁÁÀº ½Ã·Â ȸº¹ µîÀÇ ÀÌÁ¡À¸·Î ÀÎÇØ 2023³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ¿ëµµº°·Î´Â Fuchs Dystrophy ºÐ¾ß°¡ 2022³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí 2023³âºÎÅÍ 2030³â±îÁö °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÀÌ·¯ÇÑ ¼ºÀåÀº ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÇ Ã¤Åà Áõ°¡¿Í ÀÌ ÁúȯÀÇ ³ôÀº À¯º´·ü µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ Å« ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå °¢¸· ÀÓÇöõÆ® ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °¢¸· ÀÓÇöõÆ® : À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- Àΰ£ °¢¸·
- ÇÕ¼º
Á¦5Àå °¢¸· ÀÓÇöõÆ® ½ÃÀå : ¼ö¼ú ¹æ¹ýº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ÀüÃþ °¢¸· ¼ºÇü¼ú
- ³»ÇÇ °¢¸· À̽ļú
Á¦6Àå °¢¸· ÀÓÇöõÆ® ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ¿øÃß°¢¸·
- Ç«½º µð½ºÆ®·ÎÇÇ
- °¨¿°¼º °¢¸·¿°
- °¢¸· ±Ë¾ç
- ±âŸ
Á¦7Àå °¢¸· ÀÓÇöõÆ® ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- °¢¸· ÀÓÇöõÆ® ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- º´¿ø
- ¾È°ú ¼¾ÅÍ
- ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
Á¦8Àå °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° °¢¸· ÀÓÇöõÆ® ½ÃÀå : Áß¿äÇÑ Æ÷ÀÎÆ®
- ºÏ¹Ì
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï »óȲ
- ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- Florida Lions Eye Bank
- Alcon Inc.
- Aurolab
- CorneaGen
- AJL Ophthalmic S.A.
- DIOPTEX
- Massachusetts Eye and Ear
- San Diego Eye Bank
- KeraMed, Inc.
- Presbia PLC
ksm 23.11.01
Corneal Implants Market Growth & Trends:
The global corneal implants market size is anticipated to reach USD 695.0 million by 2030, registering a CAGR of 6.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The rising prevalence of corneal diseases, such as keratoconus, Fuchs dystrophy, and infectious keratitis, is the major factor driving the industry's growth. The gap between demand and supply is also expected to boost industry growth in the long run. Various programs spreading awareness about the importance of corneal donations are also likely to support the industry's growth. Moreover, many European countries are adopting an "opt-out" policy for organ donation to meet the growing demand for corneal grafts.
An increasing number of R&D activities related to corneal implants is expected to foster industry growth over the forecast period. Bioengineered cornea, 3D printed cornea, and stem cell therapy are a few of the topics gaining attention from the stakeholders. Moreover, a favorable reimbursement scenario and increasing focus of manufacturers to develop new products and the expected launch of new products in the next two years are expected to boost the growth of the market over the forecast period. The COVID-19 pandemic led to a temporary lag in sales of corneal implants due to a fall in the number of procedures that were carried out as a precautionary measure to curb the spread of the virus.
However, with the world now returning to normalcy the market is expected to attain a pre-COVID growth rate over the forecast period. North America dominated the global industry in 2021 and accounted for the largest share of the overall revenue. The region is projected to expand further at a steady CAGR from 2022 to 2030 as the U.S is one of the major suppliers of corneal implants globally. On the other hand, the Asia Pacific region is estimated to register the fastest growth rate during the forecast period on account of the rising demand for corneal implants in countries, such as China, Indonesia, and the Philippines.
Corneal Implants Market Report Highlights:
- Based on type, the human cornea segment accounted for the largest share in 2022 and is estimated to remain dominant throughout the forecast period
- Lack of accessibility, shortage of human corneas, and rising number of graft rejection cases are factors expected to drive the segment growth
- The endothelial keratoplasty segment is expected to register the fastest CAGR from 2023 to 2030 owing to benefits, such as faster and better visual restoration with decreased risk of infection and accidents to the eye surface
- Based on applications, the Fuchs Dystrophy segment held the largest share in 2022 and is expected to register the fastest CAGR as well from 2023 to 2030
- This growth can be attributed to the factors, such as the rising adoption of minimally invasive surgical procedures and the high prevalence of the disease
- Based on end-user, the hospital segment held the largest market share in 2022 and is expected to have a significant growth rate over the forecast period
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Surgery Method
- 1.1.3. Application
- 1.1.4. End Use
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Surgery method outlook
- 2.2.3. Application outlook
- 2.2.4. End-use outlook
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Corneal Implants Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Corneal Implants Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic Landscape
Chapter 4. Corneal Implants: Type Estimates & Trend Analysis
- 4.1. Corneal Implants Market: Key Takeaways
- 4.2. Corneal Implants Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Human Cornea
- 4.3.1. Human Cornea market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Synthetic
- 4.4.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Corneal Implants Market: Surgery Method Estimates & Trend Analysis
- 5.1. Corneal Implants Market: Key Takeaways
- 5.2. Corneal Implants Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Penetrating Keratoplasty
- 5.3.1. Penetrating keratoplasty market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Endothelial Keratoplasty
- 5.4.1. Endothelial keratoplasty market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Corneal Implants Market: Application Estimates & Trend Analysis
- 6.1. Corneal Implants Market: Key Takeaways
- 6.2. Corneal Implants Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Keratoconus
- 6.3.1. Keratoconus market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Fuchs Dystrophy
- 6.4.1. Fuchs dystrophy market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Infectious Keratitis
- 6.5.1. Infectious keratitis market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Corneal Ulcers
- 6.6.1. Corneal ulcers market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Corneal Implants Market: End-use Estimates & Trend Analysis
- 7.1. Corneal Implants Market: Key Takeaways
- 7.2. Corneal Implants Market: Movement & Market Share Analysis, 2022 & 2030
- 7.3. Hospitals
- 7.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4. Ophthalmic Centers
- 7.4.1. Ophthalmic center market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Ambulatory Surgical Centers
- 7.5.1. Ambulatory surgical centers market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Corneal Implants Market: Regional Estimates & Trend Analysis
- 8.1. Regional Outlook
- 8.2. Corneal Implants Market by Region: Key Takeaways
- 8.3. North America
- 8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.2. U.S.
- 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.3. Canada
- 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.2. Germany
- 8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.3. France
- 8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.4. Italy
- 8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.5. Spain
- 8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.6. Sweden
- 8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.7. Norway
- 8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.2. China
- 8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.3. India
- 8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.4. Australia
- 8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.5. Thailand
- 8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.6. South Korea
- 8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.2. Mexico
- 8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.3. Argentina
- 8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.3. UAE
- 8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Market Participant Categorization
- 9.2.1. Florida Lions Eye Bank
- 9.2.1.1. Company overview
- 9.2.1.2. Financial performance
- 9.2.1.3. Product benchmarking
- 9.2.1.4. Strategic initiatives
- 9.2.2. Alcon Inc.
- 9.2.2.1. Company overview
- 9.2.2.2. Financial performance
- 9.2.2.3. Product benchmarking
- 9.2.2.4. Strategic initiatives
- 9.2.3. Aurolab
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Product benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. CorneaGen
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. AJL Ophthalmic S.A.
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. DIOPTEX
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Massachusetts Eye and Ear
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. San Diego Eye Bank
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. KeraMed, Inc.
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. Presbia PLC
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives